title: Miltefosine: issues to be addressed in the future.
abstract: Future issues that need to be addressed for miltefosine are efficacy against non-Indian visceral leishmaniasis, efficacy in HIV-coinfected patients, efficacy against the many forms of cutaneous and mucosal disease, effectiveness under clinical practice conditions, generation of drug resistance and the need to provide a second antileishmanial agent to protect against this disastrous event, and the ability to maintain reproductive contraceptive practices under routine clinical conditions.
authors.affiliation: bermanjo@mail.nih.gov
authors.forename: J
authors.initials: J
authors.lastname: Berman
authors.forename: A D M
authors.initials: AD
authors.lastname: Bryceson
authors.forename: S
authors.initials: S
authors.lastname: Croft
authors.forename: J
authors.initials: J
authors.lastname: Engel
authors.forename: W
authors.initials: W
authors.lastname: Gutteridge
authors.forename: J
authors.initials: J
authors.lastname: Karbwang
authors.forename: H
authors.initials: H
authors.lastname: Sindermann
authors.forename: J
authors.initials: J
authors.lastname: Soto
authors.forename: S
authors.initials: S
authors.lastname: Sundar
authors.forename: J A
authors.initials: JA
authors.lastname: Urbina
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000517:prevention & control; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D005544:Forecasting; D015658:HIV Infections / Q000150:complications; D006801:Humans; D007896:Leishmaniasis / Q000150:complications / Q000188:drug therapy*; D010767:Phosphorylcholine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000188:drug therapy
chemical_list: D000981:Antiprotozoal Agents; D010767:Phosphorylcholine; C039128:miltefosine